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Abstract. The occurrence and fate data of pharmaceuticals in the en-
vironment were described in the article. The main list of pharmaceuticals 
groups identified in surface and sewage waters was shown according to 
studies of laboratories in the U.S. and Europe. The main approaches for re-
duction of pharmaceuticals releasing into environment and monitoring of 
surface water were considered. 
Introduction. Nowadays the pharmaceutical industry and pharmacy 
is one of the most highly developed complexes of industry in the world, 
which increases the quality of life and socio-economic indicators in the so-
ciety. 
At the same time, the 50% of inhabitants in the world live in cities. 
Two-thirds of the world's population will live in urban areas by 2025. 
Moreover, the number of megalopolises (with population over 10 million 
people) also will increase from 21 to 29 by this time. 
This entails global demographic, epidemiological and economic 
changes. The biggest non-infectious epidemic in the world is diabetes, now 
there are 366 million of patients. According to epidemiological data, in 
2030 there will be more than 552 million people suffering from this disease 
in the world (http://zdorov-info.com.ua/). In accordance to data 
(http://www.oecd-ilibrary.org/) in 2009 the consumption of antidiabetes 
drugs reached 2.3 tons in Germany and 1.5 tons in UK. The basic annual 
consumption data of certain pharmaceutical groups in different countries is 
presented in Figure 1. Thus, the manufacturing of pharmaceuticals has 
reached an extremely high level, and by the latest consumption forecasts 
will be more than 100 thousand tons per year in the world. 
The main aim of this paper was summarizing the existing studies and 
occurrence data of pharmaceuticals in the environment. Based on these data 
the actual research areas and regulatory issues (e.g. monitoring, control and 
management) of pharmaceuticals were discussed for perspective. 
2 Pharmaceuticals in the environment. Because of the global pro-
duction and consumption of drugs, an extensive investigation of releasing 
pharmaceuticals mechanisms and changes into environment is being per-
formed. 
According to the results of the research (McClellan, 2010; Bendz, 
2005;Boxall, 2004) the remnants of drugs and their derivatives are found in 
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surface waters in France, USA, UK, Germany, Denmark and Sweden. The-
se substances also can be found in sewage sludge, river and ocean sedi-
ments and in the municipal landfills filtrates. Some species have been 
found even in drinking water and ice, ground and ocean waters. 
Many studies confirmed the data of the annual drug releasing into the 
environment, which counts several hundred of kilograms. The study 
(Saussereau, 2013) demonstrates the annual dumping 75.6 kg of drug 
Celiprolol, 38 kg of Tramadol, 31.9 kg of Oxazepamin the River Seine. 
 
Figure 1 – The annual consumption of different pharmaceuticals 
groups in the world, kg / year 
Such a large amount of pharmaceuticals in the environment can be 
explained by the fact that not all used drugs for human and animals treat-
ment go through biotransformation in the body. According several studies 
for this process exposed from 5 to 95% of all medicines (Kummerer, 2010, 
KummererK, 2000). 
2.1 Pharmaceuticals in surface waters. Currently in the waters of 
Europe more than 3,000 kinds of pharmaceutical shave been found. For in-
stance, recent monitoring of the rivers in Baltic Sea countries demonstrated 
containing up to µg l-1 concentrations of drugs. It concerns also the Baltic 
Sea, the waters of which washes the shores of Russia, Estonia, Latvia, 
Lithuania, Poland, Germany, Sweden, Denmark and Finland. 
Oxazepam (a benzodiazepine) has been detected near the coast of 
Stockholm at concentrations of 15–20 ng l-1 (HELCOM, 2010). Table 1 
shows the data of the presence of pharmaceuticals residues in the natural 
waters according to references. 
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Concentrations of certain pharmaceuticals were also found in fish 
and other aquatic organisms. Thus, Baltic Sea salmon has been found to 
contain 17α-ethinylestradiol at a concentration of 0.90 µg kg−1. In the Swe-
dish screening study the antibiotic substance Ciproﬂoxacin was found in 
three out of ﬁve ﬁsh samples, with an average concentration of 6 µg kg−1 
(HELCOM, 2010). The investigations of the life cycle of insects have 
shown that carbamazepine (antiepileptic drug) affects the reproduction of 
midges (gnats-Zvontsov), water mosquitoes in natural waters (Delorenzo, 
2010). 
2.2 Pharmaceuticals in the wastewaters. The content of these drugs 
in the waste water sentering into the municipal sewage treatment plants 
(STPs) is estimated tens or hundreds of times higher (Table 2). 
Table 1 – The concentrations of drugs in the natural waters 
Medical class Substance 
Concentrations, 
µg/l 
Removal 
efficiency,% 
Antibiotics 
Ciprofloxacin 0.03
4
; 0.025
5 – 
Norfloxacine 0.12
4
; 0.076
5 – 
Sulfamethoxazole 1.9
4
; 0.14
5 – 
Tetracycline 0.11
5
; – 
Anti-inflammatory drugs 
Diclofenac 1.0
4
; 0.81
5 
17–69 
Naproxen 0.39
4
;  0.074
5 
66–93 
Ibuprofen 3.4
5
; 90 
Antiseptic Triclosan 0.15
3
; 2.3
9 
55–95 
β-blockers 
Bisoprolol 2.9
4,5 – 
Metoprolol 2.2
4,5 
83 
3,4,5,9 – referencenumber 
4 Removal of pharmaceuticals at STPs. The treatment efficiency at 
STPs is significantly affected by several factors such as the physico-
chemical properties of pharmaceuticals, the treatment processes employed, 
the age of the activated sludge, the hydraulic retention time (HRT), envi-
ronmental conditions (temperature and light intensity, dilution of the 
wastewater by precipitation) and physical properties, including the com-
pound adsorption capacity in the sludge. Many STPs in Europe include on-
ly two treatments steps (physical and biological)(Zorita, 2009).In this case 
activated sludge from STPs is exposed of different pharmaceuticals groups 
for several years. Therefore, it might have some factors inefficient micro-
biological removal of these substances from the wastewaters such as the 
new drugs, which have being released each year on the market.  Some of 
them can belong to the new classes, which microbiota of STPs has never 
been interacted. It can also be one cause of some difficulties for biodegra-
dation. (Daughton,1999).  
124 
Table 2 – The concentrations of drugs in wastewaters 
Medical class Substance 
C in wastewater 
reference, µg/L 
C hospital 
wastewater 
reference, µg/L 
Antibiotics 
Ciprofloxacin 0.01
11
; 0.16
12 
3.6
12
; 54
13
 
Norfloxacine 0.01
11
; 0.23
12 
23.0
13
 
Sulfamethoxazole 0.02
11
; 0.05
12 
1,3
12
; 7.1
13
 
Tetracycline 0.02
11
; 0.3
12 
1.5
12
 
Anti-inflammatory 
drugs Antiseptic 
Diclofenac 0.16
11
; 5.45
12 
1.6
12
 
Naproxen 0.92
12 – 
Ibuprofen 0.018
12 
0.9
13 
β-blockers 
Triclosan 0.14
11 – 
Bisoprolol 0.16
11
 2.2
13
 
Metoprolol 0.2
11
 – 
11, 12, 13 – referencenumber 
5 The main sources of water pollution. The main sources of water 
pollution by pharmaceuticals and their derivatives are wastewater from 
hospitals, clinics, pharmaceutical industries and domestic sewage as well. 
However, the main percentage of pharmaceuticals dumped into 
wastewaters is coming for the hospitals. This is typical for large cities, 
where is situated a great number of hospitals and health care institutions. In 
the opinion of study (Zgorska, 2011) hospital wastewaters have in a 15 times 
higher potential ecotoxicity than the general urban have. 
In accordance to investigation of 73 pharmaceuticals from 12 differ-
ent therapeutic classes, reveals that these compounds are found in consist-
ently higher concentrations in hospital wastewaters than in urban sewage, 
particularly commonly used drugs such as analgesics and antibiotics (See 
table 2). In addition, they conﬁrm that antibiotics are one of the most criti-
cal therapeutic classes used in hospitals, being highly resistant to degrada-
tion and removal (Verlicchi, 2012). 
6 The situation in different countries. Unfortunately, nowadays in 
post-Soviet countries and as in Ukraine insufficient attention is given to 
studies of pharmaceuticals pollution and their impact on the environment. 
Currently in these countries, it is unknown real extent of water pollution by 
these substances. Therefore, the authors have calculated the concentrations 
of drugs in wastewater before and after treatment at STPs in Kharkov 
(Ukraine) (Table 3). 
Table 3 – Comparative analysis of calculated and measured concentrations of the 
pharmaceuticals to different types of flow formation 
Name of drug 
substance 
Сcal in wastewater µg/L
 Сmeas 
In river  Uda 
in Kharkiv, 
µg/L 
Сmeas 
in wastewater 
reference 
µg/L 
Removal 
efficien-
cy,% Kharkiv reference 
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Metoprolol 
 
0.03–0.59 0.1713 – 0.08–0.714,13 834 
Diclofenac 
 
0.37–6.39 
0.1–
5.4
4,17,18
 
0.23–0.6519 
0.16–
3.4
4,13,17,19 9–60
4,17,19 
Ketoprofen 0.56–9.57 0.2–0.418 0.2519 0.94–2.64,18 
15–
98
4,18,19 
Ciprofloxacin 2.1–35.8 – – 0.038–5413 – 
Ibuprofen 0.33–5.62 
3.1–
19.8
17,18
 
0.021
19 
0.5–174,13,17,18 
66–
93
4,18,19 
4, 13, 17, 18, 19
 – reference number 
The calculated theoretical concentrations of pharmaceutical in the 
wastewaters are good coinciding with measured concentrations. The theo-
retical concentrations of Diclofenac and Ketoprofen are correlated on 88–
89% with the determined concentrations of instrumental way in the surface 
waters of the Uda River in Kharkov, Ukraine. The obtained convergences 
of the results are agreed with literature data for the corresponding type of 
calculations (Muthanna, 2008). 
7 The monitoring of pharmaceuticals. Monitoring of quality water 
resources, made by the State, usually involves an integrated approach and 
determination of organic pollutants such as phenol, benzene, xylene, tolu-
ene, methanol etс, but there is absent the list of pharmaceuticals measure-
ments for the sewage and surface waters. 
Today, the European Commission of the EU Framework Directive for 
Water, 2000/60/EC proposed only four pharmaceuticals drug (diclofenac, 
ibuprofen, and ethinylestradiol estradiol) as candidates to be included in the 
list of priority substances (followed by controlling release into the environ-
ment)  (Falås P., 2012).Among the substances that have also enough data to 
classify them as hazardous for the aquatic environment and requiring for 
monitoring are diclofenac, ethinylestradiol, ibuprofen, ivermectin, 
metoprolol, norethisterone, oxytetracycline, tylosin and paracetamol. 
Taking into account this fact, it is necessary to monitor natural water 
in national and also in the international framework. It is required the devel-
opment of especially common monitoring policy for that common natural 
waters in which are dumped wastewaters and for which made drinking water 
abstraction. It should be also important for countries, where all major rivers 
are the transboundary (Western Dvina, Dnepr, Seversky Donets and Don). 
8 Treatment methods. According to the properties of pharmaceuti-
cals and their derivatives scientists have developed and applied different 
treatment methods for removal resistant organic molecules from 
wastewaters: 
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1) filtration (use of membranes, micro-filters, ultrafiltration); 
2) sorption (mineral and molecular polymers, activated charcoal); 
3) oxidation; 
4) biological treatment. 
But there is no universal method guaranteeing for a treatment of all 
pharmaceuticals and the removal of the most stable drugs molecules will be 
still low (Vystavna, 2012). 
For example, removal rates on the Membrane bioreactor (MBR) 
treatment ranged from 55% to 80% for different groups of antibiotics 
(Schroder H. Fr., 2012). Therefore, persistent pharmaceuticals in small 
concentrations are discharged from the wastewater into the environment. 
This discharge could be reduced with the application of additional post 
treatment steps using advanced treatment techniques, e. g., adsorption on 
activated carbon, ozone oxidation or advanced oxidation processes(AOP) 
(Schroder 2012). 
9 Conclusion and recommended interventions. The water pollu-
tion by pharmaceuticals is the issue of the day. 
Essentially, the investigations of negative impact of pharmaceutical sub-
stances and their derivatives on aquatic organisms have been performed during 
more than 15 years and showed an extremely negative presence of any drugs in 
the waters. 
Therefore, the implementation of AOP for wastewater treatment can 
be used on the local levels including hospitals and other medical institu-
tions. Also, this can be used for sewage water purification of modern 
apartment building and it should be considered in the design and construc-
tion of household sewage systems. 
Summing it up, the actual research areas can be: 
 studying the sources of pharmaceuticals pollutants and deter-
mination of their concentrations in the wastewaters; 
 estimation of drug influence on the waters and organisms; 
 developing the methods of improving the wastewater efficien-
cy from micropollutants at the STPs; 
 development the technologies of the local wastewaters treat-
ment contained hard  biodegradable substances; 
 extension of the research and improvement of monitoring of 
natural waters related to the presence of pharmaceuticals. 
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